
Synthesis, characterisation and antimicrobial activity of conjugates between fluoroquinolones and staphyloferrin-type siderophores

Stephen J. Milner^a, Alexandra Seve^a, Anna M. Snelling^b, Gavin H. Thomas^c, Kevin G. Kerr^{b, d}, Anne Routledge^{a*}, Anne-Kathrin Duhme-Klair^{a*}

Data for (2*R*)-2, 5-bis({[(*tert*-butoxy)carbonyl]amino})pentanoic acid (2a).




¹**H NMR** (CDCl₃, 400 MHz) δ_{H} 9.21 (1H, br s, H-1), 5.25 (1H, d, ³*J*_{H-H} = 7.40 Hz, H-13), 4.80 (1H, br s, H-7), 4.32 (1H, br s, H-3), 3.14-3.13 (2H, br m, H-6), 1.87-1.87 (1H, br m, H-4), 1.73-1.61 (1H, br m, H-4), 1.59-1.56 (2H, m, H-5), 1.43 (18H, s, H-10, 11, 12, 16, 17, 18).

¹³C NMR (CDCl₃, 100 MHz) δ_C 175.93 (C=O, C-2), 156.57 (C=O, C-14), 155.83 (C=O, C-8), 80.25 (4°-C, C-14), 79.74 (4°-C, C-9), 53.09 (CH, C-3), 40.07 (CH₂, C-6), 29.96 (CH₂, C-4), 28.52 (CH₃, C-16, 17, 18), 28.46 (CH₃, C-10, 11, 12), 26.17 (CH₂, C-5).

c8373sjm: SJM-16-04-10 [DBD-Ornithine]


Acquisition Freq. = 399.785 MHz (ECS-spectrometer)




(ppm)

c8388sjm: SJM-16-04-10 [DBD-Ornithine]

Acquisition Freq. = 100.535 MHz (ECS-spectrometer)




Data for (2S)-2,5-bis({[(*tert*-butoxy)carbonyl]amino})pentanoic acid (2b).



¹**H NMR** (CDCl₃, 400 MHz) $\delta_{\rm H}$ 7.57 (1H, br s, H-1), 5.27 (1H, d, ${}^{3}J_{\rm H-H}$ = 6.72 Hz, H-13), 4.81 (1H, br s, H-7), 4.32 (1H, br s, H-3), 3.14-3.11 (2H, br m, H-6), 1.87 (1H, br s, H-4), 1.72-1.63 (1H, m, H-4), 1.61-1.51 (2H, m, H-5), 1.43 (18H, s, H-10, 11, 12, 16, 17, 18).


¹³C NMR (CDCl₃, 100 MHz) δ_C 175.87 (C=O, C-2), 156.44 (C=O, C-14), 155.80 (C=O, C-8), 80.11 (4°-C, C-15), 79.57 (4°-C, C-9), 53.09 (CH, C-3), 40.06 (CH₂, C-6), 29.88 (CH₂, C-4), 28.46 (CH₃, C-16, 17, 18), 28.40 (CH₃, C-10, 11, 12), 25.98 (CH₂, C-5).

k2981sjm: DBL-Ornithine [SJM-22-06-10]




Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is © The Royal Society of Chemistry 2013 d0363sjm: DBL-Ornithine [SJM-22-06-10]

Acquisition Freq. = 100.535 MHz




Data for (2S)-2, 6-bis({[(tert-butoxy)carbonyl]amino})hexanoic acid (2c).



¹**H NMR** (CDCl₃, 400 MHz) δ_H 5.27 (1H, br s, H-*14*), 4.68 (1H, br s, H-*8*), 4.29 (1H, br s, H-*3*), 3.12-3.11 (2H, br m, H-*7*), 1.84 (1H, br s, H-*4*), 1.73-1.71 (1H, br m, H-*4*), 1.50 (2H, br s, H-*5*), 1.44 (20H, s, H-*6*, *11*, *12*, *13*, *17*, *18*, *19*).

¹³C NMR (CDCl₃, 100 MHz) δ_C 176.37 (C=O, C-2), 156.44 (C=O, C-15), 155.96 (C=O, C-9), 80.14 (4°-C, C-16), 79.49 (4°-C, C-10), 53.34 (CH, C-3), 40.21 (CH₂, C-7), 32.13 (CH₂, C-4), 29.62 (CH₂, C-6), 28.52 (CH₃, C-17, 18, 19), 28.46 (CH₃, C-11, 12, 13), 22.51 (CH₂, C-5).

k2997sjm: DBL-Lysine [SJM-23-03-10]




d0942sjm: DBL-Lysine [SJM-23-03-10]


Acquisition Freq. = 100.535 MHz

• 、






Data for Methyl 7-{4-[(2*R*)-2,5-bis({[(*tert*-butoxy)carbonyl]amino})pentanoyl]piperazin-1-yl}-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (5a).



¹**H NMR** (CDCl₃, 400 MHz) δ_{H} 8.55 (1H, s, H-4), 8.06 (1H, d, ${}^{3}J_{H-F}$ = 13.1 Hz, H-8), 7.27 (1H, d, ${}^{4}J_{H-F}$ = 6.12 Hz, H-11), 5.41 (1H, d, ${}^{3}J_{H-H}$ = 8.56 Hz, H-30), 4.67-4.64 (1H, m, H-20), 4.62 (1H, br s, H-24), 3.98-3.95 (1H, m, H-13/16), 3.91 (3H, s, H-18), 3.84-3.81 (1H, m, H-13/16), 3.75-3.66 (2H, m, H-13/16), 3.45-3.40 (1H, m, H-3), 3.27-3.11 (6H, m, H-14, 15, 23), 1.73-1.71 (2H, br m, H-21), 1.57-1.57 (2H, br m, H-22), 1.43 (9H, s, H-33, 34, 35), 1.41 (9H, s, H-27, 28, 29), 1.36-1.32 (2H, m, H-1/2), 1.16-1.12 (2H, m, H-1/2).


¹³C NMR (CDCl₃, 100 MHz) δ_C 173.07 (C=O, C-6), 170.80 (C=O, C-19), 166.33 (C=O, C-17), 156.15 (C=O, C-31), 155.66 (C=O, C-25), 153.39 (*ipso*-Ar, d, ¹J_{C-F} = 249 Hz, C-9), 148.56 (CH, C-4), 143.99 (*ipso*-Ar, d, ²J_{C-F} = 10.7 Hz, C-10), 138.03 (*ipso*-Ar, C-5), 123.63 (*ipso*-Ar, d, ³J_{C-F} = 6.90 Hz, C-7), 113.53 (CH, d, ²J_{C-F} = 23.0 Hz, C-8), 110.18 (*ipso*-Ar, C-12), 105.34 (CH, C-11), 79.94 (4°-C, C-32), 79.34 (4°-C, C-26), 52.16 (CH₃, C-18), 50.36 (CH₂, C-13/16), 49.86 (CH₂, C-13/16), 49.64 (CH, C-20), 45.51 (CH₂, C-14, 15), 41.99 (CH₂, C-23), 34.67 (CH, C-3), 30.78 (CH₂, C-21), 28.49 (CH₃, C-33, 34, 35), 28.43 (CH₃, C-27, 28, 29), 25.94 (CH₂, C-22), 8.25 (CH₂, C-1, 2).

k2364sjm: DBD-Orn-Cpf-Me [SJM-27-04-10-B]




k5189sjm: DBD-Orn-Cpf-Me [SJM-27-04-10-B]

Acquisition Freq. = 100.535 MHz




Data for methyl 7-{4-[(2S)-2,5-bis({[(*tert*-butoxy)carbonyl]amino})pentanoyl]piperazin-1-yl}-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (5b).




¹H NMR (CDCl₃, 400 MHz) δ_H 8.52 (1H, s, H-4), 8.01 (1H, d, ${}^{3}J_{H-F} = 13.1$ Hz, H-8), 7.25 (1H, d, ${}^{4}J_{H-F} = 7.24$ Hz, H-11), 5.42 (1H, d, ${}^{3}J_{H-H} = 8.60$ Hz, H-30), 4.65 (2H, br s, H-20, 24), 3.97-3.93 (1H, m, H-14/15), 3.89 (3H, s, H-18), 3.83-3.80 (1H, br m, H-14/15), 3.74-3.66 (2H, br m, H-14/15), 3.45-3.40 (1H, m, H-3), 3.26-3.10 (6H, br m, H-13, 16, 23), 1.88 (1H, br s, H-21), 1.74-1.71 (1H, br m, H-21), 1.58-1.56 (2H, br m, H-22), 1.42 (9H, s, H-33, 34, 35), 1.40 (9H, s, H-27, 28, 29), 1.35-1.31 (2H, m, H-1/2), 1.15-1.11 (2H, m, H-1/2).


¹³C NMR (CDCl₃, 100 MHz) δ_{C} 173.07 (C=O, C-6), 170.80 (C=O, C-19), 166.44 (C=O, C-17), 156.14 (C=O, C-31), 155.66 (C=O, C-25), 153.42 (*ipso*-Ar, d, ¹*J*_{C-F} = 249 Hz, C-9), 148.59 (CH, C-4), 144.01 (*ipso*-Ar, d, ²*J*_{C-F} = 9.97 Hz, C-10), 138.06 (*ipso*-Ar, C-5), 123.74 (*ipso*-Ar, d, ³*J*_{C-F} = 6.91 Hz, C-7), 113.63 (CH, d, ²*J*_{C-F} = 22.2 Hz, C-8), 110.29 (*ipso*-Ar, C-12), 105.31 (CH, C-11), 79.95 (4°-C, C-32), 79.35 (4°-C, C-26), 52.21 (CH₃, C-18), 50.37 (CH₂, C-13/16), 49.90 (CH₂, C-23), 49.66 (CH, C-20), 45.54 (CH₂, C-14/15), 42.01 (CH₂, C-14/15), 40.14 (CH₂, C-13/16), 34.66 (CH, C-3), 30.84 (CH₂, C-21), 28.50 (CH₃, C-33, 34, 35), 28.46 (CH₃, C-27, 28, 29), 25.98 (CH₂, C-22), 8.29 (CH₂, C-1, 2).

d5552sjm: DBL-Orn-Cpf-Me [SJM-05-08-10]






Data for methyl 7-{4-[(2S)-2,6-bis({[(*tert*-butoxy)carbonyl]amino})hexanoyl]piperazin-1-yl}-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (5c).




¹H NMR (CDCl₃, 400 MHz) δ_{H} 8.49 (1H, s, H-4), 7.96 (1H, d, ³*J*_{H-F} = 13.1 Hz, H-8), 7.24 (1H, d, ⁴*J*_{H-F} = 7.04 Hz, H-11), 5.44 (1H, d, ³*J*_{H-H} = 8.52 Hz, H-31), 4.68 (1H, br s, H-25), 4.63-4.58 (1H, m, H-20), 3.95-3.92 (1H, br m, H-13/16), 3.87 (3H, s, H-18), 3.80-3.77 (1H, br m, H-13/16), 3.70-3.69 (2H, br m, H-13/16), 3.44-3.39 (1H, m, H-3), 3.26-3.18 (4H, br m, H-14, 15), 3.16-3.03 (2H, br m, H-24), 1.72-1.66 (1H, m, H-21), 1.59-1.54 (1H, m, H-21), 1.54-1.46 (2H, m, H-22), 1.42 (11H, s, H-23, 34, 35, 36), 1.39 (9H, s, H-28, 29, 30), 1.32-1.29 (2H, m, H-1/2), 1.14-1.10 (2H, m, H-1/2).


¹³C NMR (CDCl₃, 100 MHz) δ_{C} 173.03 (C=O, C-6), 170.91 (C=O, C-19), 166.29 (C=O, C-17), 156.17 (C=O, C-32), 155.74 (C=O, C-26), 153.38 (*ipso*-Ar, d, ¹*J*_{C-F} = 249 Hz, C-9), 148.55 (CH, C-4), 143.99 (*ipso*-Ar, d, ²*J*_{C-F} = 10.7 Hz, C-10), 138.01 (*ipso*-Ar, C-5), 123.59 (*ipso*-Ar, d, ³*J*_{C-F} = 6.91 Hz, C-7), 113.47 (CH, d, ²*J*_{C-F} = 22.2 Hz, C-8), 110.13 (*ipso*-Ar, C-12), 105.34 (CH, d, ³*J*_{C-F} = 2.30 Hz, C-11), 79.88 (4°-C, C-33), 79.17 (4°-C, C-27), 52.13 (CH₃, C-18), 50.33 (CH₂, C-13/16), 49.87 (CH₂, C-12/15), 49.82 (CH, C-20), 45.48 (CH₂, C-14, 15), 41.94 (CH₂, C-24), 34.66 (CH, C-3), 33.21 (CH₂, C-21), 29.64 (CH₂, C-23), 28.49 (CH₃, C-34, 35, 36), 28.44 (CH₃, C-28, 29, 30), 22.43 (CH₂, C-22), 8.23 (CH₂, C-1, 2).

k5176sjm: DBL-Lys-Cpf-Me [SJM-20-04-10]







Data for methyl 7-{4-[(2S)-2,5-bis({[(*tert*-butoxy)carbonyl]amino})pentanoyl]piperazin-1-yl}-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (5d).




¹H NMR (CDCl₃, 400 MHz) δ_{H} 8.43 (1H, s, H-3), 8.08 (1H, d, ${}^{3}J_{H-F}$ = 12.9 Hz, H-7), 6.73 (1H, d, ${}^{4}J_{H-F}$ = 6.64 Hz, H-10), 5.42 (1H, d, ${}^{3}J_{H-H}$ = 8.56 Hz, H-29), 4.66 (2H, br s, H-19, 23), 4.20 (2H, q, ${}^{3}J_{H-H}$ = 7.24 Hz, H-2), 3.95 (1H, br s, H-12/15), 3.90 (3H, s, H-17), 3.83-3.79 (1H, br m, H-12/15), 3.74-3.66 (2H, m, H-12/15), 3.24-3.13 (6H, m, H-13, 14, 22), 1.91 (1H, br s, H-20), 1.73-1.71 (1H, br m, H-20), 1.58-1.56 (2H, m, H-21), 1.53 (3H, t, ${}^{3}J_{H-H}$ = 7.24 Hz, H-1), 1.42 (9H, s, H-32, 33, 34), 1.40 (9H, s, H-26, 27, 28). ¹³C NMR (CDCl₃, 100 MHz) δ_{C} 173.08 (C=O, C-5), 170.81 (C=O, C-18), 166.64 (C=O, C-16), 156.15 (C=O, C-30), 155.67 (C=O, C-24), 153.28 (*ipso*-Ar, d, ${}^{1}J_{C-F}$ = 249 Hz, C-8), 148.50 (CH, C-3), 144.28 (*ipso*-Ar, d, ${}^{2}J_{C-F}$ = 10.7 Hz, C-9), 136.15 (*ipso*-Ar, C-4), 124.60 (*ipso*-Ar, d, ${}^{3}J_{C-F}$ = 6.90 Hz, C-6), 114.08 (CH, d, ${}^{2}J_{C-F}$ = 23.0 Hz, C-7), 110.41 (*ipso*-Ar, C-11), 104.40 (CH, C-10), 79.95 (4°-C, C-31), 79.35 (4°-C, C-25), 52.24 (CH₃, C-17), 50.43 (CH₂, C-12/15), 50.02 (CH₂, C-12/15), 49.63 (CH, C-19), 49.12 (CH₂, C-2), 45.52 (CH₂, C-13, 15), 42.02 (CH₂, C-22), 30.82 (CH₂, C-20), 28.51 (CH₃, C-32, 33, 34), 28.46 (CH₃, C-26, 27, 28), 25.98 (CH₂, C-21), 14.57 (CH₃, C-1).


d0250sjm: DBL-Orn-Nrf-Me [SJM-13-07-10]








Data for 2-({[(2*R*)-1-[4-(3-carboxy-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl]-5-(3,4-dicarboxy-3-hydroxybutanamido)-1-oxopentan-2-yl]carbamoyl}methyl)-2-hydroxybutanedioic acid (9a).




¹H NMR (D₂O, 400 MHz) δ_H 8.47 (1H, s, H-4), 7.64 (1H, d, ³J_{H-F} = 12.2 Hz, H-8), 7.46 (1H, d, ⁴J_{H-F} = 6.12 Hz, H-11), 4.87-4.84 (1H, br s, H-20), 3.89-3.76 (4H, br m, H-13, 16), 3.63-3.47 (2H, br m, H-3, 14/15), 3.39-3.26 (3H, br m, H-14/15), 3.22-3.15 (2H, m, H-23), 2.79-2.44 (8H, m, H-26, 31, 36, 41), 1.75-1.66 (2H, br m, H-21), 1.60-1.52 (2H, br m, H-22), 1.34-1.33 (2H, m, H-1/2), 1.08 (2H, br s, H-1/2).

¹³**C** NMR (D₂O, 100 MHz) δ_{C} 181.44 (C=O), 181.28 (C=O), 179.80 (C=O), 173.63 (C=O), 173.39 (C=O), 172.84 (C=O), 154.12 (*ipso*-Ar, ¹*J*_{C-F} = 248 Hz, C-9), 148.19 (CH, C-4), 145.07 (*ipso*-Ar, d, ²*J*_{C-F} = 10.7 Hz, C-10), 139.65 (*ipso*-Ar, C-5), 114.26 (*ipso*-Ar, C-7), 112.09 (CH, d, ²*J*_{C-F} = 23.0 Hz, C-8), 107.51 (CH, C-11), 76.05 (4°-C, C-37), 75.89 (4°-C, C-27), 50.71 (CH, C-20), 50.34 (CH₂, C-23), 46.34 (CH₂, C-14/15), 45.52 (CH₂, C-13/16), 45.03 (CH₂, C-13/16), 43.01 (CH₂, C-31, 41), 39.96 (CH₂, C-26/36), 39.73 (CH₂, C-26/36), 39.15 (CH₂, C-23), 36.14 (CH, C-3), 28.14 (CH₂, C-21), 25.53 (CH₂, C-22), 8.38 (CH₂, C-1, 2).


13551sjm: 2(1,3-C)-D-Orn-Cpf [SJM-22-02-11]



Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is C The Royal Society of Chemistry 2013 n3570sjm: 2(1,3-C)-D-Orn-Cpf [SJM-22-02-11]




Data for 2-({[(2S)-1-[4-(3-carboxy-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl]-5-(3,4-dicarboxy-3-hydroxybutanamido)-1-oxopentan-2-yl]carbamoyl}methyl)-2-hydroxybutanedioic acid (9b).




¹H NMR (D₂O, 400 MHz) δ_H 8.46 (1H, s, H-4), 7.64 (1H, d, ${}^{3}J_{H-F}$ = 12.2 Hz, H-8), 7.46 (1H, d, ${}^{4}J_{H-F}$ = 6.12 Hz, H-11), 4.85-4.88 (1H, br s, H-20), 3.86-3.75 (4H, br m, H-13, 16), 3.60-3.49 (2H, br m, H-3, 14/15), 3.40-3.27 (3H, br m, H-14/15), 3.21-3.16 (2H, m, H-23), 2.81-2.45 (8H, m, H-26, 31, 36, 41), 1.76-1.66 (2H, br m, H-21), 1.58-1.52 (2H, br m, H-22), 1.34-1.34 (2H, m, H-1/2), 1.06 (2H, br s, H-1/2).

¹³**C** NMR (D₂O, 100 MHz) δ_{C} 181.56 (C=O), 181.29 (C=O), 179.78 (C=O), 173.61 (C=O), 173.39 (C=O), 172.85 (C=O), 154.16 (*ipso*-Ar, ¹*J*_{C-F} = 248 Hz, C-9), 148.23 (CH, C-4), 145.05 (*ipso*-Ar, d, ²*J*_{C-F} = 10.7 Hz, C-10), 139.67 (*ipso*-Ar, C-5), 114.25 (*ipso*-Ar, C-7), 112.11 (CH, d, ²*J*_{C-F} = 23.0 Hz, C-8), 107.52 (CH, C-11), 76.06 (4°-C, C-37), 75.89 (4°-C, C-27), 50.70 (CH, C-20), 50.36 (CH₂, C-23), 46.35 (CH₂, C-14/15), 45.54 (CH₂, C-13/16), 45.05 (CH₂, C-13/16), 43.02 (CH₂, C-31, 41), 39.97 (CH₂, C-26/36), 39.73 (CH₂, C-26/36), 39.16 (CH₂, C-23), 36.16 (CH, C-3), 28.16 (CH₂, C-21), 25.54 (CH₂, C-22), 8.38 (CH₂, C-1, 2).


m7841sjm: 2(1,3-C)-L-Orn-Cpf [SJM-24-02-11]





(ppm)


Data for 2-({[(2S)-1-[4-(3-carboxy-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl]-6-(3,4-dicarboxy-3-hydroxybutanamido)-1-oxohexan-2-yl]carbamoyl}methyl)-2-hydroxybutanedioic acid pentasodium salt (9c).




¹**H NMR** (D₂O, 400 MHz) δ_H 8.43 (1H, s, H-4), 8.35-8.34 (1H, br m, H-32), 7.59 (1H, d, ${}^{3}J_{H-F}$ = 12.9 Hz, H-8), 7.41 (1H, d, ${}^{4}J_{H-F}$ = 6.84 Hz, H-11), 7.29-7.24 (1H, br m, H-24), 4.79 (1H, br s, H-19), 3.89-3.76 (4H, br m, H-13, 16), 3.55 (1H, br s, H-3), 3.45-3.26 (4H, br m, H-14/15, 23), 3.16-3.12 (2H, m, H-14/15), 2.76-2.44 (8H, m, H-26, 30, 34, 38), 1.74-1.73 (2H, br m, H-20), 1.53-1.47 (2H, br m, H-22), 1.45-1.37 (2H, br m, H-21), 1.33-1.31 (2H, m, H-1/2), 1.06-1.00 (2H, m, H-1/2).


¹³C NMR (D₂O, 100 MHz) δ_C 180.60 (C=O), 180.44 (C=O), 179.38 (C=O), 172.64 (C=O), 172.52 (C=O), 172.25 (C=O), 153.20 (*ipso*-Ar, ¹*J*_{C-F} = 249 Hz, C-9), 147.28 (CH, C-4), 144.14 (*ipso*-Ar, d, ²*J*_{C-F} = 10.7 Hz, C-10), 138.70 (*ipso*-Ar, C-5), 120.93 (*ipso*-Ar, C-7), 111.19 (CH, d, ²*J*_{C-F} = 23.0 Hz, C-8), 106.57 (CH, C-11), 75.19 (4°-C, C-35), 75.02 (4°-C, C-27), 49.83 (CH, C-19), 49.46 (CH₂, C-23), 48.79 (CH₂, C-14/15), 45.46 (CH₂, C-13/16), 44.62 (CH₂, C-30, 38), 44.13 (CH₂, C-26, 34), 42.12 (CH₂, C-13/16), 39.15 (CH₂, C-14/15), 35.25 (CH, C-3), 30.84 (CH₂, C-23), 28.14 (CH₂, C-22), 22.40 (CH₂, C-21), 7.50 (CH₂, C-1, 2).

d5104sjm: 2(1,3-C)-L-Lys-Cpf [SJM-07-02-11]






Data for 2-({[(2S)-1-[4-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl]-5-(3,4-dicarboxy-3-hydroxybutanamido)-1-oxopentan-2-yl]carbamoyl}methyl)-2-hydroxybutanedioic acid pentasodium salt (9d).



¹H NMR (D₂O, 400 MHz) δ_{H} 8.53 (1H, s, H-3), 7.88 (1H, d, ³*J*_{H-F} = 13.1 Hz, H-7), 7.14 (1H, d, ⁴*J*_{H-F} = 6.40 Hz, H-10), 4.88-4.75 (1H, m, H-18), 4.42 (2H, br q, ³*J*_{H-H} = 13.7, 6.72 Hz, H-2), 3.95-3.74 (4H, m, H-12, 15), 3.40-3.31 (4H, m, H-13, 14), 3.20-3.19 (2H, m, H-21), 2.75-2.42 (8H, m, H-24, 28, 32, 36), 1.74-1.68 (2H, m, H-19), 1.64-1.52 (2H, m, H-20), 1.47 (3H, t, ³*J*_{H-H} = 7.32 Hz, H-1). ¹³C NMR (D₂O, 100 MHz) δ_{C} 181.27 (C=O, C-6), 179.80 (C=O, C-16), 179.12 (C=O, C-31), 176.32 (C=O, C-23), 173.65 (C=O, C-34), 173.41 (C=O, C-26), 172.87 (C=O, C-37), 172.39 (C=O, C-29), 154.09 (*ipso*-Ar, ¹*J*_{C-F} = 249 Hz, C-8), 148.03 (CH, C-3), 145.50 (*ipso*-Ar, d, ²*J*_{C-F} = 10.7 Hz, C-9), 137.82 (*ipso*-Ar, C-4), 122.43 (*ipso*-Ar, C-6), 112.40 (CH, d, ²*J*_{C-F} = 23.8 Hz, C-7), 106.77 (CH, C-10), 76.05 (4°-C, C-33), 75.89 (4°-C, C-25), 50.74 (CH₂, C-13, 14), 50.53 (CH₂, C-2), 50.42 (CH, C-18), 46.34 (CH₂, C-12/15), 45.52 (CH₂, C-32, 36), 45.02 (CH₂, C-24, 28), 43.06 (CH₂, C-12/15), 39.73 (CH₂, C-21), 29.46 (CH₂, C-19), 25.54 (CH₂, C-20), 14.60 (CH₃, C-1).

m7842sjm: 2(1,3-C)-L-Orn-Nrf [SJM-01-03-11]






Table S1. Activity of the methyl-ester of ciprofloxacin (3), the methyl-ester of norfloxacin (4) and conjugates 6c and 6d in a disc diffusion assay.

Bacterial Strain	Diameter of zone of inhibition (mm)			
	3 ^a	4 ^b	6c ^a	6d ^b
Staphylococcus aureus (Oxford) NCTC 6571	R	R	R	R
Staphylococcus aureus NCTC 10399	R	R	R	11
Staphylococcus aureus HG-1 ^{c,d}	R	R	R	R
Staphylococcus aureus NCTC 13142°	R	R	R	R
Staphylococcus aureus NCTC 13143 ^{c,d}	R	R	R	R
Staphylococcus aureus BIG 0052 ^{c,d}	R	R	R	R
Staphylococcus epidermidis NCTC 11047	R	R	R	R
Staphylococcus epidermidis NCTC 2749	R	R	R	R
Staphylococcus haemolyticus NCTC 11042	R	R	R	14
Escherichia coli NCTC 10418	R	R	10	8
Escherichia coli BIG 0046 ^d	R	R	R	R
Escherichia coli BIG 0051 ^d	R	R	R	R
Pseudomonas aeruginosa NCTC 6749	R	R	R	R
Pseudomonas aeruginosa BIG 0039	R	R	R	R
Pseudomonas aeruginosa BIG 0037	R	R	R	R
Pseudomonas aeruginosa NCTC 10662	R	R	R	R
Pseudomonas aeruginosa BIG 0063	R	R	R	R
Serratia marcescens NCTC 1377	R	R	R	R
Burkholderia cepacia NCTC 10744	R	R	R	R

R = resistant, zone of inhibition = 0 mm. ^aCompound discs equimolar with 5 µg ciprofloxacin were used in the assay. ^bCompound discs equimolar with 5 µg norfloxacin were used in the assay. ^cMethicillin-resistant *S. aureus* (MRSA). ^dStrains of clinical origin defined as resistant to ciprofloxacin by CLSI criteria.